171 related articles for article (PubMed ID: 25022598)
1. Hematologic response and stabilization of renal function in a patient with light chain deposition disease after lenalidomide treatment: a novel therapeutic approach?
Gkotzamanidou M; Terpos E; Kastritis E; Dimopoulos MA
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):e179-81. PubMed ID: 25022598
[No Abstract] [Full Text] [Related]
2. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.
Kumar SK; Hayman SR; Buadi FK; Roy V; Lacy MQ; Gertz MA; Allred J; Laumann KM; Bergsagel LP; Dingli D; Mikhael JR; Reeder CB; Stewart AK; Zeldenrust SR; Greipp PR; Lust JA; Fonseca R; Russell SJ; Rajkumar SV; Dispenzieri A
Blood; 2012 May; 119(21):4860-7. PubMed ID: 22504925
[TBL] [Abstract][Full Text] [Related]
3. Light chain deposition disease affecting the gastrointestinal tract in the setting of post-living donor kidney transplantation.
Jimenez-Zepeda VH; Vajpeyi R; John R; Trudel S
Int J Hematol; 2012 Jul; 96(1):125-31. PubMed ID: 22573235
[TBL] [Abstract][Full Text] [Related]
4. Renal crescentic alpha heavy chain deposition disease: a report of 3 cases and review of the literature.
Alexander MP; Nasr SH; Watson DC; Méndez GP; Rennke HG
Am J Kidney Dis; 2011 Oct; 58(4):621-5. PubMed ID: 21944962
[TBL] [Abstract][Full Text] [Related]
5. Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.
Hogan JJ; Weiss BM
Clin J Am Soc Nephrol; 2016 Sep; 11(9):1681-1691. PubMed ID: 27416775
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease.
Cohen C; Royer B; Javaugue V; Szalat R; El Karoui K; Caulier A; Knebelmann B; Jaccard A; Chevret S; Touchard G; Fermand JP; Arnulf B; Bridoux F
Kidney Int; 2015 Nov; 88(5):1135-43. PubMed ID: 26176826
[TBL] [Abstract][Full Text] [Related]
7. Light chain deposition disease without detectable light chains in serum or urine. Report of a case and review of the literature.
van Ingen G; van Bronswijk H; Meijer CJ; Stel HV
Neth J Med; 1991 Oct; 39(3-4):142-7. PubMed ID: 1791875
[TBL] [Abstract][Full Text] [Related]
8. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease.
Kimura S; Ohkawara H; Ogawa K; Tanaka M; Sano T; Harada-Shirado K; Takahashi H; Ueda K; Shichishima-Nakamura A; Matsumoto H; Ikeda K; Kazama JJ; Hashimoto Y; Ikezoe T
Intern Med; 2018 Dec; 57(24):3651-3657. PubMed ID: 30101913
[TBL] [Abstract][Full Text] [Related]
10. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors.
Pozzi C; D'Amico M; Fogazzi GB; Curioni S; Ferrario F; Pasquali S; Quattrocchio G; Rollino C; Segagni S; Locatelli F
Am J Kidney Dis; 2003 Dec; 42(6):1154-63. PubMed ID: 14655186
[TBL] [Abstract][Full Text] [Related]
11. Treatment of idiopathic light chain deposition disease: complete remission with bortezomib and dexamethasone.
Souto Filho JT; Monteiro JM; Andrade IB
J Bras Nefrol; 2016 Dec; 38(4):450-454. PubMed ID: 28001187
[TBL] [Abstract][Full Text] [Related]
12. Reversal of dialysis-dependent renal failure in light-chain deposition disease by autologous peripheral blood stem cell transplantation.
Firkin F; Hill PA; Dwyer K; Gock H
Am J Kidney Dis; 2004 Sep; 44(3):551-5. PubMed ID: 15332228
[TBL] [Abstract][Full Text] [Related]
13. [Deposition of light chains in various organs; light chain deposition disease].
van Klaveren RJ; Holdrinet RS; Assmann KJ
Ned Tijdschr Geneeskd; 1989 May; 133(18):943-6. PubMed ID: 2498673
[TBL] [Abstract][Full Text] [Related]
14. Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
Kleber M; Ihorst G; Udi J; Koch B; Wäsch R; Engelhardt M
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):38-48. PubMed ID: 22054851
[TBL] [Abstract][Full Text] [Related]
15. Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens.
Ziogas DC; Kastritis E; Terpos E; Roussou M; Migkou M; Gavriatopoulou M; Spanomichou D; Eleutherakis-Papaiakovou E; Fotiou D; Panagiotidis I; Kafantari E; Psimenou E; Boletis I; Vlahakos DV; Gakiopoulou H; Matsouka C; Dimopoulos MA
Leuk Lymphoma; 2017 Aug; 58(8):1832-1839. PubMed ID: 27967286
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic plasmacytoma with biliary obstruction as a manifestation of multiple myeloma relapse.
Castellani L; Burgësser MV; Guanchiale L; Benavidez A; de Diller AB; Basquiera AL; Balderramo D
Gastroenterol Hepatol; 2014; 37(6):357-9. PubMed ID: 24746707
[No Abstract] [Full Text] [Related]
17. Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide.
Weisel KC; Böckeler M; Bianchi L; Terracciano LM; Mayer F; Kanz L
Int J Hematol; 2009 Jan; 89(1):91-94. PubMed ID: 19101782
[TBL] [Abstract][Full Text] [Related]
18. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
[TBL] [Abstract][Full Text] [Related]
19. Light Chain Deposition Disease After Kidney Transplantation With Long Graft Survival: Case Report.
Kuppachi S; Holanda D; Thomas CP
Transplant Proc; 2016; 48(1):255-8. PubMed ID: 26915878
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.
Kaposztas Z; Kahan BD; Katz SM; Van Buren CT; Cherem L
Transplant Proc; 2009 Dec; 41(10):4407-10. PubMed ID: 20005409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
